JP2013543842A5 - - Google Patents

Download PDF

Info

Publication number
JP2013543842A5
JP2013543842A5 JP2013534442A JP2013534442A JP2013543842A5 JP 2013543842 A5 JP2013543842 A5 JP 2013543842A5 JP 2013534442 A JP2013534442 A JP 2013534442A JP 2013534442 A JP2013534442 A JP 2013534442A JP 2013543842 A5 JP2013543842 A5 JP 2013543842A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
halo
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013534442A
Other languages
English (en)
Japanese (ja)
Other versions
JP5802756B2 (ja
JP2013543842A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2011/054675 external-priority patent/WO2012052948A1/en
Publication of JP2013543842A publication Critical patent/JP2013543842A/ja
Publication of JP2013543842A5 publication Critical patent/JP2013543842A5/ja
Application granted granted Critical
Publication of JP5802756B2 publication Critical patent/JP5802756B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013534442A 2010-10-20 2011-10-19 スムーズンド受容体モジュレーターとしてのピリジン−2−誘導体 Expired - Fee Related JP5802756B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40510110P 2010-10-20 2010-10-20
US61/405,101 2010-10-20
PCT/IB2011/054675 WO2012052948A1 (en) 2010-10-20 2011-10-19 Pyridine- 2- derivatives as smoothened receptor modulators

Publications (3)

Publication Number Publication Date
JP2013543842A JP2013543842A (ja) 2013-12-09
JP2013543842A5 true JP2013543842A5 (enExample) 2014-11-06
JP5802756B2 JP5802756B2 (ja) 2015-11-04

Family

ID=44936320

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013534442A Expired - Fee Related JP5802756B2 (ja) 2010-10-20 2011-10-19 スムーズンド受容体モジュレーターとしてのピリジン−2−誘導体

Country Status (6)

Country Link
US (1) US9056865B2 (enExample)
EP (1) EP2630134B9 (enExample)
JP (1) JP5802756B2 (enExample)
CA (1) CA2813162C (enExample)
ES (1) ES2543151T3 (enExample)
WO (1) WO2012052948A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
SG10201605163PA (en) 2011-06-22 2016-08-30 Purdue Pharma Lp Trpv1 antagonists including dihydroxy substituent and uses thereof
US9695178B2 (en) * 2013-01-15 2017-07-04 Suzhou Kintor Pharmaceuticals, Inc. 6-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-D]pyrimidine analogs as hedgehog pathway signaling inhibitors and therapeutic applications thereof
CN103588771B (zh) * 2013-01-15 2016-01-27 苏州云轩医药科技有限公司 具有刺猬通路拮抗剂活性的嘧啶类抗肿瘤化合物
CN103333117B (zh) * 2013-05-18 2015-11-25 嘉兴中科化学有限公司 一种4[(4-氯-2-嘧啶基)氨基]苯腈的制备方法
EP3039019B1 (en) * 2013-08-26 2020-04-22 Purdue Pharma L.P. Azaspiro[4.5]decane derivatives and use thereof
US10093646B2 (en) 2014-01-17 2018-10-09 Novartis Ag 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
ES2699354T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-(triazin-3-il/piridazin-3-il)-piper(-azin)idina y composiciones de las mismas para inhibir la actividad de SHP2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
ES2805232T3 (es) 2015-06-19 2021-02-11 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
EP3310779B1 (en) 2015-06-19 2019-05-08 Novartis AG Compounds and compositions for inhibiting the activity of shp2
ES2824576T3 (es) 2015-06-19 2021-05-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
CN109415360B (zh) 2016-06-14 2021-11-02 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
JP7034953B2 (ja) * 2016-07-05 2022-03-14 バイエル・クロップサイエンス・アクチェンゲゼルシャフト ハロゲン化ピリジン誘導体の製造方法
US20190343836A1 (en) 2017-01-10 2019-11-14 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
US12319686B2 (en) 2019-01-17 2025-06-03 Hoffmann-La Roche Inc. Process for the preparation of tetrahydropyridopyrimidines
WO2022194259A1 (en) * 2021-03-18 2022-09-22 Sironax Ltd. Receptor-interacting protein 1 inhibitors, preparations, and uses thereof

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
CA2179029C (en) 1993-12-30 2009-02-24 Philip W. Ingham Vertebrate embryonic pattern-inducing hedgehog-like proteins
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
US6281332B1 (en) 1994-12-02 2001-08-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
DK0821671T3 (da) 1995-04-20 2001-04-23 Pfizer Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ES2183905T3 (es) 1995-12-20 2003-04-01 Hoffmann La Roche Inhibidores de metaloproteasa de matriz.
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
ATE211134T1 (de) 1996-03-05 2002-01-15 4-anilinochinazolin derivate
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
ES2191187T3 (es) 1996-07-13 2003-09-01 Glaxo Group Ltd Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa.
JP4386967B2 (ja) 1996-07-13 2009-12-16 グラクソ、グループ、リミテッド プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物
HUP9903014A3 (en) 1996-07-18 2000-08-28 Pfizer Phosphinate derivatives having matrix metalloprotease inhibitor effect and medicaments containing the same
US6153609A (en) 1996-08-23 2000-11-28 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
AU5131998A (en) 1997-01-06 1998-08-03 Pfizer Inc. Cyclic sulfone derivatives
ES2202796T3 (es) 1997-02-03 2004-04-01 Pfizer Products Inc. Derivados de acidos arilsulfonilaminohidroxamicos.
JP2000507975A (ja) 1997-02-07 2000-06-27 ファイザー・インク N−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
BR9807678A (pt) 1997-02-11 2000-02-15 Pfizer Derivados de ácidos arilsulfonil-hidroxâmicos
JP2002511852A (ja) 1997-05-07 2002-04-16 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節剤としての2−インドリノン誘導体
AU734009B2 (en) 1997-05-30 2001-05-31 Merck & Co., Inc. Novel angiogenesis inhibitors
ATE368665T1 (de) 1997-08-22 2007-08-15 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
CA2303830A1 (en) 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
NZ520093A (en) 1997-11-11 2004-03-26 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
IL139934A (en) 1998-05-29 2007-10-31 Sugen Inc History 2 - Indulinone converted to pyrrole and pharmaceutical preparations containing them
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
MXPA02012870A (es) 2000-06-22 2003-05-14 Pfizer Prod Inc Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal.
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
EP1871762A2 (en) * 2005-04-18 2008-01-02 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
EP2121626A1 (en) 2006-12-15 2009-11-25 Pfizer Products Inc. Benzimidazole derivatives
ES2609258T3 (es) 2007-06-29 2017-04-19 Pfizer Inc. Derivados de bencimidazol
US20090281089A1 (en) * 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
EA019507B1 (ru) * 2008-05-13 2014-04-30 Айрм Ллк Конденсированные азотсодержащие гетероциклы и содержащие их композиции в качестве ингибиторов киназы
US20120094974A1 (en) * 2008-06-17 2012-04-19 Wei Chen Smoothened receptor modulators
GB0813740D0 (en) * 2008-07-28 2008-09-03 Angeletti P Ist Richerche Biologica Therapeutic compounds
JP2013503846A (ja) 2009-09-01 2013-02-04 ファイザー・インク ベンズイミダゾール誘導体
US9881309B2 (en) 2012-03-13 2018-01-30 American Express Travel Related Services Company, Inc. Systems and methods for tailoring marketing
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys
JP6943759B2 (ja) 2017-12-28 2021-10-06 株式会社東海理化電機製作所 シフト装置

Similar Documents

Publication Publication Date Title
JP2013543842A5 (enExample)
JP2013032389A5 (enExample)
JP2016537382A5 (enExample)
PH12018500106A1 (en) Ethynyl derivatives as metabotropic glutamate receptor modulators
JP2014501766A5 (enExample)
JP2015501820A5 (enExample)
JP2015042636A5 (ja) 有機化合物
JP2015500843A5 (enExample)
JP2013505929A5 (enExample)
JP2017511321A5 (enExample)
JP2013533253A5 (enExample)
JP2013537203A5 (enExample)
JP2015520140A5 (enExample)
JP2015143283A5 (enExample)
JP2009263394A5 (enExample)
JP2016518328A5 (enExample)
JP2017515901A5 (enExample)
JP2012144574A5 (enExample)
JP2012526168A5 (enExample)
JP2017501236A5 (enExample)
JP2011518833A5 (enExample)
JP2017514910A5 (enExample)
JP2016528273A5 (enExample)
JP2017538689A5 (enExample)
JP2015500842A5 (enExample)